AIM ImmunoTech sees promising results in Ampligen combo for pancreatic cancer
Seeking Alpha News (Thu, 19-Sep 8:54 AM ET)
AstraZeneca Fasenra gains additional indication
Seeking Alpha News (Wed, 18-Sep 2:44 PM ET)
AstraZeneca's Asthma Drug Gets FDA Approval For Rare Disease Of Blood Vessel Inflammation
Benzinga (Wed, 18-Sep 12:05 PM ET)
AstraZeneca: A Buy Rating Based on Promising Pipeline and Regulatory Prospects
TipRanks (Wed, 18-Sep 10:55 AM ET)
FASENRA approved in the US for eosinophilic granulomatosis with polyangiitis
Business Wire (Wed, 18-Sep 7:00 AM ET)
AstraZeneca: Strong Oncology Pipeline Fuels Growth and Outperformance – Buy Rating Endorsed
TipRanks (Wed, 18-Sep 5:25 AM ET)
Globe Newswire (Tue, 17-Sep 11:23 AM ET)
Barclays Sticks to Its Buy Rating for AstraZeneca (AZN)
TipRanks (Tue, 17-Sep 1:55 AM ET)
J.P. Morgan Reaffirms Their Buy Rating on AstraZeneca (AZN)
TipRanks (Mon, 16-Sep 4:55 PM ET)
AstraZeneca Imfinzi + Imjudo combo shows long-term liver cancer survival benefit
Seeking Alpha News (Mon, 16-Sep 3:40 PM ET)
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, immunology and rare diseases. The majority of sales come from international markets with the United States representing close to one third of its sales.
Astrazeneca PLC - American Depositary Shares trades on the NASDAQ stock market under the symbol AZN.
As of September 19, 2024, AZN stock price climbed to $78.84 with 2,493,065 million shares trading.
AZN has a beta of 0.41, meaning it tends to be less sensitive to market movements. AZN has a correlation of 0.08 to the broad based SPY ETF.
AZN has a market cap of $244.26 billion. This is considered a Mega Cap stock.
Last quarter Astrazeneca PLC - American Depositary Shares reported $13 billion in Revenue and $.99 earnings per share. This beat revenue expectation by $233 million and missed earnings estimates by -$.21.
In the last 3 years, AZN stock traded as high as $87.68 and as low as $52.65.
The top ETF exchange traded funds that AZN belongs to (by Net Assets): QQQ, QQQM, PPH, DFIC, AVDE.
AZN has underperformed the market in the last year with a price return of +20.5% while the SPY ETF gained +29.8%. AZN has also underperformed the stock market ETF in the last 3 month and 2 week periods returning +1.2% and -8.1%, respectively, while the SPY returned +4.4% and +3.6%, respectively.
AZN support price is $77.63 and resistance is $79.53 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that AZN stock will trade within this expected range on the day.